Celularity Inc. Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Celularity Inc. (CELU) reported Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized of -$6.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized · last filed 2026-04-30
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2025-03-31 was -$1.61M, a 228.26% decline year-over-year.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2024-03-31 was $1.26M, a 8.00% increase year-over-year.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2023-03-31 was $1.16M, a 27.76% decline year-over-year.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2022-03-31 was $1.61M, a 1.77% decline year-over-year.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2025 was -$6.39M.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2024 was -$5.50M.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2023 was -$4.74M, a 203.47% decline from fiscal 2022.
- Celularity Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2022 was $4.58M, a 65.60% decline from fiscal 2021.
| Period end | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 3 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 6 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 9 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$6.39M 10-K · filed 2026-04-30 | ||||
| 2025-09-30 | -$4.58M 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | -$2.82M 10-Q · filed 2025-08-29 | ||||
| 2025-03-31 | -$1.61M 10-Q · filed 2025-08-29 | ||||
| 2024-12-31 | -$5.50M 10-K · filed 2026-04-30 | ||||
| 2024-09-30 | $3.62M 10-Q · filed 2024-12-06 | ||||
| 2024-06-30 | $2.43M 10-Q · filed 2024-11-07 | ||||
| 2024-03-31 | $1.26M 10-Q · filed 2024-10-16 | ||||
| 2023-12-31 | -$4.74M 10-K · filed 2025-05-08 | $4.74M 10-K · filed 2024-07-30 | |||
| 2023-09-30 | $3.51M 10-Q · filed 2024-12-06 | ||||
| 2023-06-30 | $2.26M 10-Q · filed 2024-11-07 | ||||
| 2023-03-31 | $1.16M 10-Q · filed 2024-10-16 | ||||
| 2022-12-31 | $4.58M 10-K · filed 2024-07-30 | ||||
| 2022-09-30 | $3.40M 10-Q · filed 2024-01-03 | ||||
| 2022-06-30 | $2.23M 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $1.61M 10-Q · filed 2023-05-22 | ||||
| 2021-12-31 | $13.31M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $12.16M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $3.57M 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | $1.64M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $5.92M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $3.90M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |